C07D 513/00
Heterocyclic compounds containing in the condensed system at least one hetero ring
Official title: Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
C07D513/00 (Heterocyclic compounds containing in the condensed system at least one hetero ring) appears on 5,146 US grants and 5,502 published applications in this corpus.
Search patents in C07D- Granted patents
- 5,146
- Published applications
- 5,502
- Assignees
- 1,843
- Inventors
- 16,305
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 38 | 0 |
| 1977 | 31 | 0 |
| 1978 | 53 | 0 |
| 1979 | 46 | 0 |
| 1980 | 38 | 0 |
| 1981 | 46 | 0 |
| 1982 | 45 | 0 |
| 1983 | 30 | 0 |
| 1984 | 41 | 0 |
| 1985 | 55 | 0 |
| 1986 | 47 | 0 |
| 1987 | 44 | 0 |
| 1988 | 61 | 0 |
| 1989 | 64 | 0 |
| 1990 | 63 | 0 |
| 1991 | 60 | 0 |
| 1992 | 61 | 0 |
| 1993 | 68 | 0 |
| 1994 | 55 | 0 |
| 1995 | 72 | 0 |
| 1996 | 91 | 0 |
| 1997 | 123 | 0 |
| 1998 | 95 | 0 |
| 1999 | 63 | 0 |
| 2000 | 50 | 0 |
| 2001 | 61 | 16 |
| 2002 | 74 | 78 |
| 2003 | 87 | 145 |
| 2004 | 67 | 174 |
| 2005 | 75 | 171 |
| 2006 | 81 | 174 |
| 2007 | 100 | 184 |
| 2008 | 92 | 154 |
| 2009 | 101 | 217 |
| 2010 | 158 | 241 |
| 2011 | 135 | 254 |
| 2012 | 190 | 221 |
| 2013 | 183 | 211 |
| 2014 | 212 | 280 |
| 2015 | 235 | 254 |
| 2016 | 201 | 231 |
| 2017 | 225 | 220 |
| 2018 | 180 | 238 |
| 2019 | 189 | 243 |
| 2020 | 181 | 266 |
| 2021 | 177 | 228 |
| 2022 | 138 | 235 |
| 2023 | 150 | 316 |
| 2024 | 161 | 306 |
| 2025 | 156 | 266 |
| 2026 | 97 | 179 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Orexin receptor agonists and uses thereof29 Sep 2026US 12,747,252 B2Jazz Pharmaceuticals Ireland Limited
- Rock inhibitor and preparation method therefor and use thereof15 Sep 2026US 12,735,414 B2Wuhan Ll Science and Technology Development Co., Ltd.
- Materials for organic electroluminescent devices15 Sep 2026US 12,735,436 B2Universal Display Corporation
- Inhibitor of apoptosis (IAP) protein antagonists8 Sep 2026US 12,729,208 B2Sanford Burnham Prebys Medical Discovery Institute
- Voltage sensitive thiazolothiazole dyes and associated synthetic methods8 Oct 2026US 2026/0308176 A1
- Thiazolopyridin-7(4h)-one wrn inhibitors8 Oct 2026US 2026/0308177 A1Nimbus Wadjet, Inc.
- Biarylamide derivatives and their use as pkmyt1 inhibitors1 Oct 2026US 2026/0297042 A1Cancer Research Technology Limited
- Cyclic vinyl sulfone wrn inhibitors1 Oct 2026US 2026/0297070 A1Nimbus Wadjet, Inc.
- Bicyclic compounds as cdk inhibitors1 Oct 2026US 2026/0297080 A1BeOne Medicines I GmbH
Most cited
By later US patents
- Precursor to nucleic acid probe282US 4,754,065 ACetus Corporation · 1988
- Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof270US 6,110,929 A3M Innovative Properties Company · 2000
- Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family225US 5,654,307 AWarner-Lambert Company · 1997
- Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents219US 5,552,422 AMerck Frosst Canada, Inc. · 1996
- Heterocyclic compounds useful as inhibitors of tyrosine kinases202US 6,506,769 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2003